Abeona Therapeutics Inc. develops and commercializes cell and gene therapies for serious diseases. Its updates center on ZEVASKYN (prademagene zamikeracel), an autologous cell-based gene therapy for wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa, including qualified treatment center activations, commercial launch activity, manufacturing and patient-treatment progress.
Company news also covers financial results, corporate progress, employee inducement equity awards under Nasdaq rules, board and committee changes, and development work involving AAV-based gene therapies and next-generation AAV capsids for ophthalmic and other serious diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the acceptance of three abstracts for presentation at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), scheduled for May 16-20, 2023, in Los Angeles, CA. The abstracts highlight preclinical data for investigational gene therapy candidates from its adeno-associated virus (AAV) ophthalmology program, including ABO-504 for Stargardt disease, ABO-503 for X-linked retinoschisis, and ABO-505 for autosomal dominant optic atrophy. The company is submitting pre-IND meeting requests to the FDA and anticipates discussions in Q2 2023. This engagement is intended to advance their gene therapy programs aimed at addressing serious genetic eye diseases.
Abeona Therapeutics (ABEO) reported its 2022 financial results and outlined key corporate objectives in a press release dated March 29, 2023. The company plans to submit a Biologics License Application (BLA) for EB-101, aimed at treating recessive dystrophic epidermolysis bullosa (RDEB), to the FDA by late 2Q/early 3Q 2023, buoyed by positive Phase 3 VIITAL study results. Financial highlights include cash positions of $52.5 million and a net loss of $43.5 million for 2022. Abeona aims to advance drug candidates for eye diseases while strengthening its management team with new executive appointments.